- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Sera Prognostics outlines plan to expand partner programs to 15-17 states by year-end 2026 while maintaining cash runway through 2028 | 1 | Seeking Alpha | ||
| Mi | Sera Prognostics: Aktie fällt trotz Gewinnüberraschung nach schwachen Umsatzzahlen | 2 | Investing.com Deutsch | ||
| Mi | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter And Full Year 2025 Financial Results | 156 | PR Newswire | SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| Mi | Sera Prognostics: EPS übertrifft Schätzungen um 0,03 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| Mi | SERA PROGNOSTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| Mi | SERA PROGNOSTICS, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| Mi | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.01. | Sera Prognostics: Positive Studiendaten zu Frühgeburtentest beflügeln Aktie | 1 | Investing.com Deutsch | ||
| 07.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 15.12.25 | Jefferies initiates Sera Prognostics stock with Buy rating on preterm birth test | 1 | Investing.com | ||
| 15.12.25 | Jefferies stuft Sera Prognostics mit "Buy" ein - Frühgeburtentest als Kurstreiber | 3 | Investing.com Deutsch | ||
| 14.11.25 | Sera Prognostics outlines accelerated Medicaid pilot expansion to 13 states as commercialization momentum builds | 1 | Seeking Alpha | ||
| 13.11.25 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2025 Financial Results | 774 | PR Newswire | SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 13.11.25 | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 01.10.25 | Sera Prognostics Appoints Tiffany Inglis As CMO | - | RTTNews | ||
| 01.10.25 | Sera Prognostics appoints Dr. Tiffany Inglis as chief medical officer | 1 | Investing.com | ||
| 01.10.25 | Sera Prognostics, Inc.: Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer | 165 | PR Newswire | SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy... ► Artikel lesen | |
| 06.08.25 | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2025 Financial Results | 134 | PR Newswire | SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 08.05.25 | Sera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial Officer | 308 | PR Newswire | Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company®... ► Artikel lesen | |
| 07.05.25 | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial Results | 386 | PR Newswire | SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,435 | +0,35 % | NanoRepro: Neue Strategie rund um PHLAS | NanoRepro ist vielen Investoren noch als Anbieter von Corona-Schnelltests bekannt. Doch das Unternehmen hat sich strategisch neu positioniert. Im Podcast "NebenwerteWelt im Gespräch" erläutert CEO Lisa... ► Artikel lesen | |
| OCUGEN | 1,759 | +1,24 % | Ocugen, Inc. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 27,835 | -0,50 % | Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics | ||
| COSCIENS BIOPHARMA | 0,795 | -19,70 % | COSCIENS Biopharma Inc.: COSCIENS Provides Strategic Update | TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company") today announced that the Company has made a strategic decision... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 8,404 | -2,87 % | BioCryst (BCRX) Rallies 7.10% on Acquisition Buzz | ||
| VAXART | 0,410 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen | |
| IBIO | 1,720 | -6,01 % | Jones Trading reiterates iBio stock rating on pulmonary hypertension expansion | ||
| ARBUTUS BIOPHARMA | 3,688 | -0,05 % | Moderna Reaches $2.25 Bln Patent Settlement With Genevant, Arbutus | WASHINGTON (dpa-AFX) - Moderna, Inc. (MRNA) has agreed to pay $950 million upfront and up to an additional $1.3 billion under a $2.25 billion global settlement with Genevant Sciences, a subsidiary... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,320 | 0,00 % | RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,540 | -0,90 % | Cardiff Oncology, Inc.: Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer | ||
| MANNKIND | 2,178 | +1,73 % | MannKind Announces Settlement of Convertible Senior Notes | DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal... ► Artikel lesen | |
| ALDEYRA | 1,569 | -2,64 % | What's Going On With Aldeyra Therapeutics Stock On Thursday? | ||
| TRAWS PHARMA | 2,130 | +0,95 % | Traws Pharma, Inc.: Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal ... | Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID- with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,349 | +2,94 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen |
SERA PROGNOSTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,830 Euro und damit +1,10 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.